UnitedHealthcare Community Plan

Clinical Pharmacy Program Guidelines for Preferred Non-Solid Dosage Forms

Program	Prior Authorization
Medication	Preferred Non-Solid Dosage Forms
Markets in Scope	Arizona, California, Hawaii, Maryland, Nevada, New Jersey, New York, New York EPP, Pennsylvania- CHIP, South Carolina
Issue Date	3/2014
Pharmacy and Therapeutics Approval Date	3/2020
Effective Date	5/2020

1. Background:

Many medically necessary drugs are specially formulated for convenience of use in the pediatric population. Formulations include but are not limited to oral suspensions, oral solutions, patches, chewable, orally disintegrating, sprinkle capsules, etc. The formularies/PDLs of the health plans administered by UnitedHealthcare Community Plan are intended to provide the highest quality care while containing cost. UnitedHealthcare Community Plan will limit certain pediatric intended special drug formulations with an age limitation. Patients whose age exceeds the age limitation will require transition to a preferred product or a prior authorization to continue use of the age limited product.

UnitedHealthcare Community Plan requires age limitations for the drug therapies that are typically intended for pediatric convenience of use in order to promote high quality cost effective care, and to monitor utilization. This procedure enhances formulary/PDL compliance and appropriate prescribing. Eligibility for reimbursement is based upon a clinical review protocol established by the UnitedHealthcare Community Plan Pharmacy and Therapeutics Committee.

2. Coverage Criteria:

A. <u>Approval Criteria</u>

1. **<u>One</u>** of the following:

a. Requested drug must be used for an FDA-approved indication

-OR-

b. The use of this drug is supported by information from the appropriate compendia of current literature†

-AND-

2. The drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans' program

-AND-

3. The drug is being prescribed within the manufacturer's published dosing guidelines or falls within dosing guidelines found in the compendia of current literature†

-AND-

4. **One** of the following:

a. **Both** of the following:

(1) The patient is able to swallow a solid dosage form

-AND-

(2) **One** of the following:

- History of failure, contraindication, or intolerance to at least **three** preferred solid oral dosage forms. Prior trials of formulary/PDL alternatives must sufficiently demonstrate that the formulary/PDL alternatives are either ineffective or inappropriate at the time of the request. NOTE: In instances where there are fewer than three preferred alternatives, the patient must have a history of failure, contraindication, or intolerance to **all** of the preferred products.
- There are no preferred formulary alternatives for the requested drug.

-OR-

b. Patient is unable to swallow a solid dosage form

-OR-

c. Patient utilizes a feeding tube for medication administration

Authorization will be issued for 12 months.

†Compendia of current literature: • American Hospital Formulary Service Drug Information • National Comprehensive Cancer Network Drugs and Biologics Compendium • Thomson Micromedex DrugDex • Clinical Pharmacology • United States Pharmacopeia-National Formulary (USP-NF)

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

Program	Prior Authorization
Change Control	
Date	Change
3/2014	New policy
11/2016	Annual review, updated policy template and changed name of policy from Special Formulations with Age Limitations to Non-Solid Dosage Forms
1/2017	Annual review. No changes to clinical criteria.
11/2017	Updated non-preferred language to ensure that non-preferred non-solid oral dosage formulations step through preferred non-solid oral dosage formulations.
3/2018	Updated Community Plan language in the background. Rearranged indication(s) and dosing criteria. Separated criteria into preferred and non-preferred products and updated trial/fail language.
7/2018	Updated formatting in support by compendia literature section
3/2019	Removed non-preferred section as this should be evaluated using global non-preferred criteria.
3/2020	Updated title to include the word “Preferred”. Updated list of compendia.